Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Insights from NGLY1 deficiency could provide new approach to treat blood cancers

A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise. But it is hobbled by a problem that also plagues other cancer drugs: targeted cells can develop resistance.

25 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Stand Up To Cancer has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute to investigate a revolutionary new method of treating pancreatic cancer, one of the most aggressive of all cancers.

13 Oct 2017

Cancers linked to obesity account for 40% of all cancers in the US, report states

Being obese or overweight is linked to an increased risk of developing 13 types of cancer, according to the latest Vital Signs report from the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute. These cancers accounted for approximately 40% of all cancers diagnosed in the US, in 2014.

4 Oct 2017

Researchers explore new combination approach to treat high-risk soft-tissue sarcomas

University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors.

20 Sep 2017

Categories of Preference included for recommendations within NCCN Guidelines

The National Comprehensive Cancer Network has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology. Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma.

15 Sep 2017

Researcher develops bone marrow models to study hematological and musculoskeletal diseases

For her research on the development of hematological and musculoskeletal disorders, Dr. Cornelia Lee-Thedieck, scientist at Karlsruhe Institute of Technology, is awarded an ERC Starting Grant: The European Research Council decided to fund her project "bloodANDbone" with EUR 1.5 million for five years. At KIT's Institute of Functional Interfaces, Lee-Thedieck develops models of the human bone marrow to study the regeneration of blood and bone by stem cells and how this regeneration is disturbed in diseases like leukemia or bone metastases.

6 Sep 2017

Immune booster could improve effectiveness of vaccines and cancer immunotherapy

Vaccines and cancer immunotherapies do essentially the same thing: They boost a person's immune system, better enabling it to fight an offender, be it microbe or malignancy.

29 Aug 2017

‘Breakthrough’ leukemia drug also portends ‘quantum leap’ in cost

When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like "breakthrough," "revolutionary" and "a watershed moment."

23 Aug 2017

Promising brain cancer vaccine developed at Roswell Park receives orphan drug status from FDA

The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at Roswell Park Cancer Institute.

8 Aug 2017

Shaping the future of oncology treatment

Victories Over Cancer is about enabling those affected by cancer to enjoy more of life’s meaning full moments and making cancer more manageable. At Janssen, we're really thinking about the elimination of cancer, and we take a very deliberate approach to that.

2 Aug 2017

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

A Food and Drug Administration (FDA) panel created history by recommending a gene therapy for patients with cancer. In this therapy the patient’s own genes would be modified to fight the cancer cells. The patient’s cells which are thus altered to treat the cancer would thus be termed as “living drugs” as they act as soldiers to treat the cancer. These cells boost up the immune system and help the body fight the cancer.

14 Jul 2017

Scientists reveal role of cellular prion protein in development of NF2-related tumors

New research published today, 10th July 2017, online in the journal Oncogene could offer hope to the thousands of, mainly young, people affected by the hereditary condition Neurofibromatosis 2 (NF2).

10 Jul 2017

New therapeutic approach offers hope for individuals with debilitating bone cancer

An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.

29 Jun 2017

New immunotherapy sends multiple myeloma into remission

Researchers are reporting the impressive results of a new cell and gene therapy that has achieved unprecedented success in treating multiple myeloma patients. Although the study is an early one and the population only included 35 people, every one of the patients responded to the treatment and 33 (94%) were in some degree of clinical remission within two months.

6 Jun 2017

Researchers uncover new way to enhance function of immune cells to combat multiple myeloma

Researchers from Belgium led by Prof. Dirk Elewaut of the VIB-UGent Center for Inflammation Research and the team of Prof. Vanderkerken and Prof. Menu at the Hematology and Immunology lab of the VUB uncovered a new way to enhance the function of a specific type of immune cell that destroys tumors in multiple myeloma, a form of bone marrow cancer considered incurable.

1 Jun 2017

New treatment offers hope for kidney failure and transplant patients with rare disorder

A novel treatment offers kidney failure and kidney transplant patients with a rare disorder new hope. The treatment allows targeted elimination of plasma cell clones producing abnormal proteins that deposits in the kidneys and leads to kidney failure, according to new research.

3 May 2017

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

Hematologist-oncologist Ahmad Samer Al-Homsi MD, MBA, will lead a new bone marrow transplantation program at NYU Langone's Perlmutter Cancer Center for treating blood-borne cancers, including leukemia, lymphoma and multiple myeloma, and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors.

10 Apr 2017

New microfluidic technique may provide patients with less painful test for multiple myeloma

Multiple myeloma is a cancer of the plasma cells, which are white blood cells produced in bone marrow that churn out antibodies to help fight infection. When plasma cells become cancerous, they produce abnormal proteins, and the cells can build up in bone marrow, ultimately seeping into the bloodstream.

4 Apr 2017

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Insights from NGLY1 deficiency could provide new approach to treat blood cancers

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

New CAR-T cell therapy offers effective option for certain blood cancer patients

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Cancers linked to obesity account for 40% of all cancers in the US, report states

Researchers explore new combination approach to treat high-risk soft-tissue sarcomas

Categories of Preference included for recommendations within NCCN Guidelines

Researcher develops bone marrow models to study hematological and musculoskeletal diseases

Immune booster could improve effectiveness of vaccines and cancer immunotherapy

‘Breakthrough’ leukemia drug also portends ‘quantum leap’ in cost

Promising brain cancer vaccine developed at Roswell Park receives orphan drug status from FDA

Shaping the future of oncology treatment

FDA panel recommends new breakthrough gene therapy for B-cell acute lymphoblastic leukemia (ALL)

Scientists reveal role of cellular prion protein in development of NF2-related tumors

New therapeutic approach offers hope for individuals with debilitating bone cancer

New immunotherapy sends multiple myeloma into remission

Researchers uncover new way to enhance function of immune cells to combat multiple myeloma

New treatment offers hope for kidney failure and transplant patients with rare disorder

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

New microfluidic technique may provide patients with less painful test for multiple myeloma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in